User:Mfclampitt/Hollis-Eden Pharmaceuticals

Hollis-Eden Pharmaceuticals, Inc. (Hollis-Eden) is a development-stage pharmaceutical company engaged in the discovery and development of products for the treatment of diseases and disorders in which the body is unable to mount an appropriate immune or metabolic response due to disease or the process of aging. The Company is focused on the development of two clinical drug development candidates: TRIOLEX (HE3286), a next-generation compound that is in initial clinical trials for the treatment of type 2 diabetes, ulcerative colitis (UC) and rheumatoid arthritis (RA), and APOPTONE (HE3235), a next-generation compound in a clinical trial for late-stage prostate cancer. The Company's primary focus areas for compounds developed from its technology platform are in the area of inflammation.

Hollis-Eden Pharmaceuticals Inc., a development stage pharmaceutical company, engages in the discovery and development of products for the treatment of diseases and disorders, in which the body is unable to mount immune or metabolic response due to disease or the process of aging. The company focuses on developing a series of adrenal steroid hormones and hormone analogs that are derived from its Hormonal Signaling Technology Platform. It develops two clinical drug development candidates, TRIOLEX (HE3286), which is in initial clinical trials for the treatment of type 2 diabetes, ulcerative colitis, and rheumatoid arthritis; and APOPTONE (HE3235) that is in a clinical trial for late-stage prostate cancer. The company is also exploring APOPTONE for other cancers, such as breast cancer. In addition, Hollis-Eden Pharmaceuticals has a research program that is generating clinical leads for evaluation in preclinical models of various diseases, including metabolic and autoimmune conditions, as well as inflammatory diseases of the lung, bone metabolism, and regenerative medicine. The company was founded in 1992 and is headquartered in San Diego, California.

from: http://www.twst.com/ceos/AKY614.htm (hollis interview with TWST)
 * Mr. Hollis: The company was founded in 1994 and we went public in 1997. The

founding vision we had for the company then is the same as it is today, and that is to discover new chemical entities that are based on the biochemistry of endogenous adrenal steroid hormones. It is our belief that these adrenal steroid hormones have many other metabolites that are converted by tissues in the body, and that have their own unique signaling properties that regulate biology to maintain health. Being able to identify these metabolites, understand their chemical structures, signaling pathways, and their biological effects, allows us to determine if they are involved in particular diseases. The goal of our novel drug platform is TO develop those active metabolites or their synthetic analogs as pharmaceuticals to restore hormonal signaling pathways dysregulated by disease or the process of aging.